The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda, Dilan, Foltynie, Thomas·2016·Drug Discovery Today
DOI 10.1016/j.drudis.2016.01.013

Cited by (383)

Items 301–383 of 383

  1. Unravelling the novel insights between miR-7 and Parkinson’s disease (PD)
    Sakshi Kushwaha, Vikas Lakhanpal, Ajay Elangovan, Mahalaxmi Iyer, Masako Kinoshita, Arul Narayanasamy, Dibbanti HariKrishnaReddy, Zothan Siama, Mukesh Kumar Yadav, Balachandar Vellingiri · 2026 · Neurological Sciences
  2. Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study
    Arvid Engström, Henrik Svanström, Anders Peter Hviid, Björn Eliasson, Soffia Guðbjörnsdóttir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda et al. · 2026 · Diabetes Obesity and Metabolism
  3. Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer’s Disease
    Devasrita Dash, Laxminarayana Kurady Bairy, Bharti Chogtu · 2022 · Biomedical & Pharmacology Journal
  4. Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model
    А. В. Симаненкова, Фукс Оксана Станиславовна, Н. В. Тимкина, Тихомирова Полина Александровна, Timur Dmitrievich Vlasov, Т. Л. Каронова · 2023 · Arterial’naya Gipertenziya (Arterial Hypertension)
  5. Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD)
    Dahshan Hassan Selim, Hamada Ahmed Mokhlis, Abdelrahman M. Elsayed, Abdel-Aziz S. Shatat, Salama Abdou Salama, Raed Shahat Ismail · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
  6. GLP-1R as a potential link between diabetes and Alzheimer’s disease
    Shujun Li, Nanqu Huang, Mei Wang, Wendi Huang, Jingshan Shi, Yong Luo, Juan Huang · 2025 · Frontiers in Aging Neuroscience
  7. Metformin as a potential neuroprotective agent that influence Parkinson’s disease
    Bhaskar Pal, Niladri Ghatak, Chowdhury Mobaswar Hossain · 2025 · Neurological Sciences
  8. Exendin-4 inhibits the survival and invasiveness of two colorectal cancer cell lines via suppressing GS3Kβ/β-catenin/NF-κB axis through activating SIRT1
    Attalla Farag El-kott, Ayman El-Meghawry El-Kenawy, Eman R. ElBealy, Ali S. Alshehri, Heba S. Khalifa, Mashael Mohammed Bin-Meferij, Ehab El Sayed Massoud, Amira M. Al‐Ramlawy · 2021 · Biocell
  9. Therapeutic Function of Liraglutide for Mitigation of Blast-Induced Hearing Damage: An Initial Investigation in Animal Model of Chinchilla
    Shangyuan Jiang, Sarah Sanders, Paige Welch, Rong Z. Gan · 2024 · Military Medicine
  10. Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
    Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi, Dilan S. Athauda, Stephen Burgess, Thomas Foltynie, Nicholas William Wood · 2020 · medRxiv
  11. Fecal microbiota transplantation from individual with bipolar disorder and healthy control elicits distinct behaviors and metabolite profiles in mice
    Grace Bukowski-Thall, Frederike T. Fellendorf, Sarah Gorkiewicz, Kenny Chi Kin Ip, Laura Schmidt, Marija Durdević, Hansjörg Habisch, Sabrina Mörkl, Jolana Wagner‐Skacel, Susanne Bengesser et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Metabolic Psychiatry: A Conceptual Framework Targeting Metabolic Dysfunction in Psychiatric Disease
    Shebani Sethi, Michael Berk, Ana C. Andreazza, Lilianne Rivka Mujica-Parodi, Iain Campbell, Harry Campbell, Calogero Longhitano, Natalie Rasgon, Jeff S. Volek, Cynthia Victoria Calkin et al. · 2024
  13. Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers
    Andrea N Georgiou, P. Zanos, A. Onisiforou · 2025 · bioRxiv
  14. GLP‐1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes
    Pang-Shuo Perng, Yu Chang, Ming‐Tsung Chuang, Chia‐En Wong, Yuan‐Ting Sun, Hao‐Kuang Wang, Kuan‐Yu Chi, Jung‐Shun Lee, Liang‐Chao Wang, Chih‐Yuan Huang · 2025 · Stroke Vascular and Interventional Neurology
  15. Gut microbiota reconstitution and control of α-synucleinopathy with β-glucans: a promising approach for individuals with parkinson’s disease
    Faezeh Hatami, Zahra Aghelan, Majid Pouya, Melina Moulaeian, Ali Asghar Rastegari, Seyed Hosein Abtahi, Shaghayegh Hoseini · 2025 · Metabolic Brain Disease
  16. Elevated Lactobacillus salivarius and genus Akkermansia in fecal samples of Taiwanese patients with parkinson’s disease and diabetes mellitus
    Sheng-Ta Tsai, Zi-Lun Lai, Ming‐Kuei Lu, Marina R. S. Walther-Antonio, Yi-Yao Hsu, Dysan Chao, Chia-Yang Chen, Sara A. Vettleson-Trutza, John S. Kuo, Chia-Chun Yang et al. · 2025 · Scientific Reports
  17. Cardioprotective effects of Sodium-Glucose cotransporter-2 inhibitors in patients undergoing ventricular tachycardia (VT) ablation: a propensity-matched cohort study
    Muhammad Raffey Shabbir, Omer Adeeb, Ahmad Baig, Muhammad Taimur, Maria Shahzad, Ayesha Majid, Meenal Sikander, Mahrukh Imtiaz, Param Sharma, Muhammad Osama · 2025 · Journal of Interventional Cardiac Electrophysiology
  18. Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer’s disease via dual actions
    Andrea N. Georgiou, Panos Zanos, Anna Onisiforou · 2026 · Communications Medicine
  19. The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson’s disease
    Najlaa H. Almohmadi, Hayder M. Al‐kuraishy, Khulood S. Hussein, Arwa Turkistani, Fatimah M. Yousef, Ali Ismail Al-Gareeb, Ahmed M Abdelaziz, Yaser Hosny Ali Elewa, Gaber El‐Saber Batiha · 2026 · Probiotics and Antimicrobial Proteins
  20. GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy
    Roxana Mezabrovschi, Matthew E. Gegg, Anthony H.V. Schapira · 2026 · Cells
  21. Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum — Mechanisms, evidence, and future directions
    Ahmed Dahshan, Marwa Ibrahim Mahfouz Khalil, Shaimaa I. El-Jaafary, Ahmed Yamani · 2026 · Clinical Parkinsonism & Related Disorders
  22. Neuroprotective Properties of Peptides
    Oytun Erbaş, İlknur Altuntaş, Pemra Nesil, Hadi Sasanı, Mehtap Odabaşı · 2023 · IntechOpen eBooks
  23. Engineered Clostridium butyricum-pMTL007-GLP-1 Delays Neurodegeneration in Prnp-SNCA*A53T Transgenic Mice Model by Suppressing Astrocyte Senescence
    Bin Liao, Leiping Ding, Wenjing Chen, Mengyun Yue, Yun Wang, Daojun Hong, Tingtao Chen, Xin Fang · 2025 · Probiotics and Antimicrobial Proteins
  24. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting
    Naoya Kondo, Ayaka Oishi, Masahiko Hirata, Takashi Temma · 2020 · Annals of Nuclear Medicine
  25. Mitochondrial dysfunction in metabolic disorders
    Dia Advani, Sudhanshu Sharma, Rahul S. Tripathi, Rohan V. Gupta, Asmita Jaiswal, Rashmi K. Ambasta, Pravir Kumar · 2021 · Elsevier eBooks
  26. Therapies Using Anti-diabetics to Prevent and Manage Progression of Parkinson's Disease
    Monalisa Rout, Shakti Ketan Prusty, Durga Madhab Kar · 2024 · Current Drug Therapy
  27. Diet-induced obesity mediated through estrogen-related receptor α is independent of intestinal function
    Kiranmayi Vemuri, Jahangir Iqbal, Sneha Kumar, Alexandra Logerfo, Maria Ibrahim, Eileen White, Michael Paul Verzi · 2025 · Journal of Biological Chemistry
  28. Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes
    Naoya Kondo, Maiko Yonezawa, Fuko Hirano, Takashi Temma · 2025 · Molecules
  29. Effects of Liraglutide on Mitigation of Hearing Loss After Repeated Blast Exposures: A Summary of Studies in Animal Model of Chinchilla
    Shangyuan Jiang, Qunfeng Cai, Alexander G. Bien, Rong Z. Gan, Yijie Jiang · 2025 · Military Medicine
  30. GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
    Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, Yitian Yang, Shuang Lv, Mengrong Miao, Wan‐Ming Chen, Szu‐Yuan Wu, J. Zhang · 2026 · Diabetes Obesity and Metabolism
  31. “Unfolding Parkinson’s Disease Through the Microbiome-Gut-Brain Axis”
    Ramana Kamatchi Shenthilvel, Arumugam Umashankar Thangavelu, Deenathayalan Uvarajan, Mohana Mathuraj, Manish Ravikumar · 2026 · Journal of Molecular Neuroscience
  32. Converging neurotrophic-immune signaling in autism spectrum disorder: integrative roles of klotho, GDNF/GFRA-1, IGF-1 and GLP-1 pathways
    Janvi Verma, Rohit Kumar Singh, Supratim Paul, Sumedha Gupta, Abhishek Kumar Gupta, Arun Kumar Sharma, Manjeet Kumar, Sidharth Mehan, Rajaram Samant, Manoj Tongra · 2026 · Metabolic Brain Disease
  33. Branched-chain amino acids alleviate Parkinson’s neurodegeneration via microbial propionate-dependent restoration of the PI3K/Akt/mTORC1 axis
    Na Mi, Lili Ma, Jing Zhao, Xinxin Bu, Jing Xu, Jia Fu, Chao Zhang, Yali Zhang, Lifen Yao · 2026 · Molecular Immunology
  34. Comparison of prohormone processing prediction using different artificial intelligence algorithms
    Bruce R. Southey, Jonathan V. Sweedler, Sandra L. Rodriguez‐Zas · 2026 · In Silico Research in Biomedicine
  35. Parkinson's Disease: Molecular Mechanisms, Metabolic Interactions, Biomarkers, and Emerging Therapeutic Targets
    Moh Aijaz, Shmmon Ahmad · 2026 · Neurology and Clinical Neuroscience
  36. The Neuroprotective Potentials of Dual GIP/GLP1‐RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review
    Yousef Hawas, Mohamed Abouzid, Ahmed Farid Gadelmawla, Dalia Kamal Ewis, Ahmed E. Khatatbeh, Yasmin Negida, Ahmed Negida · 2026 · Brain and Behavior
  37. GLP-1-mediated delay in gastric emptying and impact on levodopa absorption in Parkinson's disease: Clinical implications
    Rodolfo Savica, Bastiaan R. Bloem · 2026 · Parkinsonism & Related Disorders
  38. REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION
    Mrugank Parmar, Shital S. Panchal · 2019 · International Research Journal of Pharmacy
  39. Differential susceptibility of human neural progenitors and neurons to ischaemic injury
    Ye Liu, Anna Michalska, Mirella Dottori, Emma D. Eaton, Jo‐Maree Courtney, Ana Antonic‐Baker, David William Howells · 2019 · Brain Research Bulletin
  40. Eficácia terapêutica do exenatide no tratamento da doença de Parkinson
    André Luiz de Lima Nascimento Alcântara, André Luiz Felipe Bezerra Cardoso, Murilo Isidoro Pinheiro Pereira, Daniela Sant’ Ana de Aquino, Andréia Biolchi Mayer · 2023 · Revista de Ciências Médicas e Biológicas
  41. Glucose handling by the brain and its implication in metabolic syndrome
    Rajarshi Mukhopadhyay, Amarta Shankar Chowdhury, Rajan Palui · 2024 · Elsevier eBooks
  42. Effect of GLP-1 receptor agonists on obesity in patients with severe mental illness: A state hospital case series of clozapine-treated patients
    Syed Sadat Ali, Narges Ghodsimaab, Matthew Rusling, Navid Rashid · 2024 · Psychiatry Research Case Reports
  43. Exenatide Stimulates Hippocampal Autophagic Activity in Alzeheimer Rat Model
    Eman Abdo, Mohamed A. Saad, Alaa El Din Firgany, Youssef Mohamed Mosaad, Sara Eldusoky · 2020
  44. The elusive pathways behind montelukast's repurposing for Alzheimer's disease
    Cátia F. Marques, M. Matilde Marques, Gonçalo C. Justino · 2022
  45. Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders
    Ernesto Fedele · 2016 · Journal of Biomolecular Research & Therapeutics
  46. Growth Factors: Neuronal Atrophy ☆
    Christian Hölscher · 2017 · Elsevier eBooks
  47. Overview of the Cross-Talk Between Hormones and Mitochondria
    Béatrice Morio, François Casas, Luc Pénicaud · 2019 · Elsevier eBooks
  48. Gut-brain axis: Central impact of gut peptides and metabolic drug on monoamine neurotransmission
    Adesina Omoloye · 2019 · DMU Open Research Archive (De Montfort University)
  49. Influence of selected drugs used in the treatment of type 2 diabetes and cardiovascular diseases on depressive disorders in elderly patients
    Daria Słomińska, Katarzyna Manikowska, Marta Hoszman, Przemysław Łukasz Mikołajczak, Hanna Winiarska · 2021 · Pharmacotherapy in Psychiatry and Neurology
  50. From Ptolemy to Copernicus: a new proposal for the care of diabetes
    Maria Chantal Ponziani · 2019 · The Journal of AMD
  51. Mitochondria-targeted drug delivery systems for the effective treatment of neurodegenerative disorders
    Vaishali Khare, Surbhi Gupta, Preeti Bisht, Debapriya Garabadu · 2022 · Elsevier eBooks
  52. Advances in Biological and Clinical Research of GLP-1 Receptor Agonists
    鑫 李 · 2022 · Advances in Clinical Medicine
  53. Faculty Opinions recommendation of Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Werner H Poewe, Philipp Mahlknecht · 2017 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  54. AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES
    Randa Ismail, Aliaa F. Anter, Asmaa Ibrahim Matouk, Gehan Hussein Heeba · 2022 · Bulletin of Pharmaceutical Sciences Assiut
  55. GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease
    Kacper Deska, Bartłomiej Bąk, Marcin Kosmalski, Tadeusz Pietras · 2023 · Postępy Higieny i Medycyny Doświadczalnej
  56. Neuroprotective potential of testosterone against aluminium chloride and d-galactose-induced Alzheimer-like pathology aggravated by overcrowding in mice: Role of Nrf2, HO-1, TNF-α, GSK-3β, PI3K and AKT pathway
    Shaimaa Rabie, Micheal Kamal Ibrahim, Hala Fahmy Zaki, Helmy M Said · 2024 · Research Square
  57. Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein—An In Silico and Experimental Approach to Parkinson’s Disease
    Sophia A. Frantzeskos, Mary A. Biggs, Ipsita A. Banerjee · 2024 · Biomimetics
  58. Neuroprotective Effect of Sitagliptin beyond the Incretin Effect: A Narrative Review
    Ali Mohammad Pourbagher‐Shahri, Fatemeh Forouzanfar · 2025 · CNS & Neurological Disorders - Drug Targets
  59. Therapeutic approaches targeting regulated cell death in neurodegenerative diseases: Current understanding and recent advances in combating neuronal loss
    Nour‐Mounira Z. Bakkar, Rowan E. Arida, Alaa Y. Soliman, Ahmed Fawzy EL‐Yazbi · 2025 · Elsevier eBooks
  60. The role of mitochondria in the pathogenesis of Parkinson's disease
    Sofia Koletsi, Giuseppe Uras, Anthony H.V. Schapira · 2025 · Handbook of behavioral neuroscience
  61. Influence of type 2 diabetes on Parkinson’s disease: emerging insights into pathogenesis and progression
    Irving Christian Rodríguez-González, Fernando Botello-Villagrana, Sergio Ruben Gomez-Villalobos, Arnulfo González‐Cantú, Ximena M. Torres-Mancilla, Francisco Alejandro Luna-Rangel, Brenda González-Bedolla, Elly Robles, Mirna González‐González, Daniel Martínez-Ramírez · 2025 · Ageing and Neurodegenerative Diseases
  62. The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials
    Joanna Pilśniak, Julia Węgrzynek‐Gallina, Błażej Bednarczyk, Aleksandra Buczek, Aleksandra Pilśniak, Tomasz Chmiela, Agnieszka Jarosińska, Joanna S. Siuda, Michał Tadeusz Holecki · 2025 · Life
  63. Additional file 1 of Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation
    Jing, Feng, Zou, Qian, Wang, Yangyang, Cai, Zhiyou, Tang, Yong · 2021 · Figshare
  64. Additional file 2 of Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease
    Hou, Yan-fang, Chang Shan, Siyue Zhuang, Zhuang, Qian-qian, Arijit Ghosh, Zhu, Ke-cheng, Kong, Xiao-ke, Wang, Shu-min, Gong, Yan-ling, Yang, Yu-ying et al. · 2021 · Figshare
  65. Additional file 1 of Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
    Vicki Wang, Tseng, Kuan-Yin, Kuo, Tung-Tai, Eagle Yi‐Kung Huang, Lan, Kuo-Lun, Chen, Zi-Rong, Ma, Kuo-Hsing, Nigel H. Greig, Jin Ho Jung, Choi, Ho-II et al. · 2024 · Figshare
  66. The anti-diabetic drug acarbose modulates the nucleation dependent amyloid fibrillation of wild-type α-synuclein
    Almas Akhtar, Payal Singh, Nikita Admane, Abhinav Grover · 2026 · Journal of Computer-Aided Molecular Design
  67. Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry
    Ana Cristina Tudosie, Loredana-Maria Marin, Simona Georgiana Popa, Andreea Loredana Golli · 2026 · International Journal of Molecular Sciences
  68. A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies
    Laura Răducu, Dragos Eugen Georgescu, Andra-Elena Balcangiu‐Stroescu, Liviu Vasile Chiperi, Ileana Adela Văcăroiu, Daniela-Gabriela Bălan, Mihai T. Georgescu, Doina Andrada Mihai, Luciana Angela Ignat, Raluca Oana Tipa · 2024 · OSF Preprints (OSF Preprints)
  69. Unlocking the potential of GSK-3β inhibitors in neurodegenerative disease prognosis: insights from glucagon-like peptide-1 receptor agonist effects
    Ahmed S. Khalifa, Ayat Ibrahim, Sarah Khalid, Abdelrahman M. Abdelfattah, Nour‐Mounira Z. Bakkar, Mohamed A. Elrewiny, Ahmed F. El-Yazbi · 2026 · Elsevier eBooks
  70. Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025
    Qinsheng Bi, L Zhang, J H Zhang, Xin Wang (91924), Changlin Zuo, Shijie Zhao, Z L Wang, Zilin Zhao, Hejia Wan · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  71. Orchestrating muscle health and nutritional integrity via companion food systems during incretin-mimetics induced weight loss
    Taemin Kim, Jeongyeon Seo, Sumin Kang, Hyun Kyung Kim, Bogyeong Lee, Junhee Lee, Gwang‐woong Go · 2026 · Food Science and Biotechnology
  72. Drugs used in treating diabetes and insulin resistance: Neurological and behavioral effects
    Tanu Dixit, Soumya Verma, Riya Kumari, Tanvi Desai, Selvan Ravindran · 2026 · Elsevier eBooks
  73. Zebrafish as a translational model for peptide-mediated synaptic dysfunction related to obesity
    Amanda Costa Rodrigues, Adriel Parahyba Lacerda, Lincoln Takashi Hota Mukoyama, Gleyce Barrios de Carvalho, Júlia Aparecida Lima da Mata, Danieli Fernanda Buccini, Octávio Luiz Franco, Ludovico Migliolo · 2026 · Frontiers in Synaptic Neuroscience
  74. Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients
    Utkan Topcu, Ferhat Oto · 2026 · Journal of Endocrinological Investigation
  75. Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study
    Yusuf Kır, Cem Haymana, Bora Torus, Bağdagül Yüksel Güler, Burak Uflaz, G Eroğlu, A. Gursoy, Esile Boyraz, Tolga Akkan, Şafak Akın et al. · 2026 · Journal of Endocrinological Investigation
  76. Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson’s disease: mechanisms and future directions
    Praveen Kumar Gaur, Prachee Raje Bisht, Sonia Lal Gupta · 2026 · Journal of Biomaterials Science Polymer Edition
  77. Parkinson’s disease—Crucial advances and on-going challenges
    Grażyna Söderbom · 2026 · International review of neurobiology
  78. A hypothesis-driven perspective on GLP-1R-β-catenin pathway crosstalk in astrocyte plasticity and endogenous neural repair
    Sudichhya Tamrakar, Laurence S. Pe, Jiraporn Panmanee, Jenq‐Lin Yang, Sujira Mukda · 2026 · Biomedicine & Pharmacotherapy
  79. Convergent Astrocytic Failure in Parkinson’s Disease: A System-Level Model of Pathogenesis and Treatment
    Ahmed M Abdelaziz, Mohamed N Fawzy, Mustafa M Shokr · 2026 · Molecular Neurobiology
  80. Genetic architecture and molecular pathogenesis of Parkinson’s disease: emerging mechanisms and therapeutic targets
    Sümeyye Yıldırım · 2026 · Metabolic Brain Disease
  81. Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research
    S. Mohana Lakshmi, Vijay Singh, Murugesan Vanangamudi, Tahreen Taj, Haleema Shahin, Rajarshi Nath, Gouranga Dutta, Sanjeeva Kumar Avvari, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy et al. · 2026 · European Journal of Neuroscience
  82. Reported effects of glucagon-like peptide-1 receptor agonists in multiple sclerosis: a scoping review of preclinical and clinical studies
    João Pedro Henriques, Maria Julia Henriques, Rafael da Cunha Gomes Ribeiro, Pedro Lucas Schimack Cosentino, Carlos Antônio Negrato · 2026 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
  83. BindingDB Entry 50008472: Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
    BindingDB · 2021 · UC San Diego